Human intravenous immunoglobulin in primary and secondary antibody deficiencies

Pediatric Infectious Disease Journal

Volumn 16, Issue 7, 1997, Pages 696-707

  Stiehm, E Richard ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Antibody deficiencies; Intravenous immunoglobulin

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; RESPIRATORY SYNCYTIAL PNEUMOVIRUS IMMUNOGLOBULIN; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; UNCLASSIFIED DRUG;

ALOPECIA; ASEPTIC MENINGITIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; CROSSOVER PROCEDURE; DYSPNEA; FLUID RETENTION; HEADACHE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; HYPERTENSION; HYPOTENSION; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LOW BIRTH WEIGHT; MALAISE; PRIORITY JOURNAL; RASH; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS; VIRUS INFECTION;

HIV INFECTIONS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE;

EID: 0030793979     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199707000-00012     Document Type: Review

References (113)

1. Bruton OC. Agammaglobulinemia. Pediatrics 1952;9:722-8.
2. Kazatchkine MD, Morell A. Intravenous immunoglobulin research and therapy. Pearl River, NY: Parthenon, 1996:391 pp.
3. Ballow M, Cates KL, Rowe JC, et al. Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res 1986;20:899-904.
4. Stiehm ER. Passive immunization. In: Feigen RD, Cherry JD, eds. Textbook of pediatric infectious diseases, ed 3. Philadelphia: Saunders, 1992;2261-88.
5. Stiehm ER. Immunodeficiency disorders general conditions. In: Stiehm ER, ed. Immunologic disorders in infants and children, ed 4. Philadelphia: Saunders, 1996:201-52.
6. Apfelweig R, Piszkiewiewics D, Hooper JA. Immunoglobulin A concentrations in commercial immune globulins. J Clin Immunol 1987;7:46-50.
7. Skavaril F, Gardi A. Differences among available immunoglobulin preparations for intravenous use. Pediatr Infect Dis 1981;7(Suppl):43-8.
8. Cunningham-Rundles C, Siegal FP, Smithwick EM, et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 1984;101:435-9.
9. Roifman CM, Lederman HM, Lavi S, et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med 1985;79:171-4.
10. Roifman CH, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987;1:1075-7.
11. Bernatowska E, Madalinski K, Janowicz W, et al. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. Clin Immunol Immunopathol 1987; 43:153-62.
12. Liese JG, Wintergerst U, Tympner KD, et al. High-vs. low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 1992;146:335-9.
13. Haeney M. Intravenous immune globulin in primary immunodeficiency. Clin Exp Immunol 1994;97(Suppl 1):11-15.
14. Ochs HD, Fischer SH, Wedgwood RJ, et al. Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 1984;76:78-82.
15. Schiff RI, Rudd C. Alterations in the half-life and clearance of IgG during therapy with intravenous gamma globulin in 16 patients with severe primary humoral immunodeficiency. J Clin Immunol 1984;6:256-64.
16. Daly PB, Evans JH, Kobayashi RH, et al. Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allergy 1991;67:504-10.
17. Kobayashi RH, Kobayashi AD, Lee N, et al. Home self-administration of intravenous immunoglobulin therapy in children. Pediatrics 1990;85:705-9.
18. Schiff RI, Sedlak D, Buckley RH. Rapid infusion of Sandoglobulin in patients with primary humoral immunodeficiency. J. Allergy Clin Immunol 1991;88:61-7.
19. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1991;331:1649-50.
20. Rosenfeld EA, Shulman ST, Corydon KE, et al. Comparative safety and efficacy of two immune globulin products in Kawasaki disease. J. Pediatr 1995;126:1000-3.
21. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Safety 1993;9:254-62.
22. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991; 325:110-17.
23. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994;97(Suppl 1):79-83.
24. Kats E, Shindo S, Eto Y, et al. Administration of immune globulin associated with aseptic meningitis. JAMA 1988; 259:3269-70.
25. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121:259-62.
26. Scribner CL, Kapit RM, Phillips ET, et al. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med 1994;121:305-6.
27. Brannagan TH, Nagle KJ, Lange DJ, et al. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47:674-7.
28. Lever AM, Webster AD, Brown D, et al. Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 1984;2:1062-4.
29. Ochs H, Fisher SH, Virant FS, et al. Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet 1985;1:404-5.
30. Trepo C, Hantz O, Vitvitski L. Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet 1986;1:322.
31. Björklander J, Cunningham-Rundles C, Lundin P, et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med 1988;84:107-11.
32. Bjøro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-11.
33. Center for Disease Control. Outbreak of hepatitis C associated with intravenous immunoglobulin administration: United States, October 1993-June 1994. MMWR 1994;43: 505-9.
34. Taliani G, Guerra E, Rosso R, et al. Hepatitis C virus infection in hypogammaglobulinemic patients receiving long-term replacement therapy with intravenous immunoglobulin. Transfusion 1995;35:103-7.
35. Meisel H, Reip A, Faltus B, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 1995;345: 1209-11.
36. Power JP, Lawlor E, Davidson F, et al. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet 1995;345:1211-13.
37. Sanchez Quijano A, Pireda JA, Lissen E, et al. Prevention of posttransfusion non A, non B hepatitis by nonspecific immunoglobulin in heart surgery. Lancet 1988;1:1245-9.
38. Slade HB. Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin Diagn Lab Immunol 1994;1:613-9.
39. Sumazaki R, Matsubara T, Aoki T, et al. Rapidly progressive hepatitis C in a patient with common variable immunodeficiency. Eur J Pediatr 1996;155:532-4.
40. Jonas MM, Baron MJ, Bresee JS, et al. Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics 1996;98:211-5.
41. Food and Drug Administration. Revised precautionary measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) by blood and blood products [Letter]. December 11, 1996, pp 1-11.
42. Gardulf A, Hammarström L, Smith CIE. Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991;338:162-6.
43. Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995;345:365-9.
44. Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 1996;98: 1127-31.
45. Imbach P. New clinical aspects of immune thrombocytopenic purpura. In: Imbach P, ed. Immunotherapy with intravenous immunoglobulins. London: Academic Press, 1991:239-43.
46. Chun JD, Lee N, Kobayashi RH, et al. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase. Ann Allergy 1993;70:462-6.
47. Mease PJ, Ochs HD, Wedgwood RJ. Successful treatment of Echovirus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia. N Engl J Med 1981;304: 1278-81.
48. Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989;321:519-21.
49. Stiehm ER, Chin TW, Haas A, et al. Infectious complications of primary immunodeficiencies. Clin Immunol Immunopathol 1986;40:69-6.
50. Meissner HC, Welliver RC, Chartrand SA, et al. Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Pediatr Infect Dis J 1996;15:1059-68.
51. Losonsky GA, Johnson JP, Winkelstein JA, et al. Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. J. Clin Invest 1985;76:2362-7.
52. Melamed I, Griffiths AM, Roifman CM. Benefit of oral immune globulin therapy in patients with immunodeficiency and chronic diarrhea. J Pediatr 1991;119:486-9.
53. Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in a allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant 1994;13:499-510.
54. Siegal FP, Oleske IM. Management of acquired immune deficiency syndrome: is there a role for immune globulins? In: Morell A, Nydegger VE, eds. Clinical use of intravenous immunoglobulins. New York: Academic Press, 1986:373-84.
55. Sandberg ET, Kline MW, Shearer WT. The secondary immunodeficiencies. In: Stiehm ER, ed. Immunologic disorders in infants and children. ed. 4. Philadelphia: Saunders, 1996:553-601.
56. Stiehm ER. Recent progress in the use of intravenous immunoglobulin. Curr Prob Pediatr 1992;22:335-48.
57. Stiehm ER. Use of immunoglobulinemia in secondary antibody deficiencies. In: Imbach P, ed. Immunotherapy with intravenous immunoglobulins. London: Academic Press, 1991:115-26.
58. Gupta A, Novick BE, Rubinstein A. Restoration of suppressor T-cell functions in children with AIDS following intravenous gamma globulin treatment. Am J Dis Child 1986; 140:143-6.
59. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991;325:73-80.
60. Spector SA, Gelber RD, McGrath N, Wara D, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med 1994;331:1181-7.
61. 9/L or more. JAMA 1992;268:483-8.
62. + lymphocyte decline in HIV-infected children in a clinical treal of IVIG infection prophylaxis. J Acquir Immune Defic Syndr 1993;6:1103-13.
63. Mofenson LM, Moye J, Korelitz J, et al. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994;13:477-84.
64. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center. Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. Pediatr Infect Dis J 1993;12:513-22.
65. Jahnke L, Applebaum S, Sherman LA, et al. An evaluation of intravenous immunoglobulin in the treatment of human immunodeficiency virus-associated thrombocytopenia. Transfusion 1994;34:759-64.
66. Lipshultz SE, Orav EJ, Sanders SP, et al. Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation 1995;92:2220-5.
67. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med 1988;319:902-7.
68. Gamm H, Huber Ch, Chapel H, et al. Intravenous immune globulin in chronic lymphocytic leukemia. Clin Exp Immunol 1994;97(Suppl):17-20.
69. Weeks JC, Tierney MR, Weinstein MC. Cost-effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991;325:81-6.
70. Chapel HM, Lee M, Hargreaves R, et al. Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet 1994;343: 1059-63.
71. Schmidt RE, Hartlapp JH, Niese D, et al. Reduction of infection frequency by intravenous gammaglobulins during intensive induction therapy for small cell carcinoma of the lung. Infection 1984;12:167-70.
72. Cannon RA, Blum PM, Ament ME, et al. Reversal of enterocolitis-associated combined immunodeficiency by plasma therapy. J Pediatr 1982;101:711-17.
73. Glinz W, Grob PVJ, Nydegger UE, et al. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. Intensive Care Med 1985; 11:288-94.
74. Munster AM. Infections in burns. In: Morell A, Nydegger UE, eds. Clinical use of intravenous immunoglobulins. New York: Academic Press, 1986:339-44.
75. Wilson NW, Ochs HD, Peterson B, et al. Abnormal primary antibody responses in pediatric trauma patients. J. Pediatr 1989;115:424-7.
76. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of Gram negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982;307:1225-30.
77. Baumgartner JD, Glauser MP, McCutchan JA, et al. Prevention of Gram negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 1985;2:59-63.
78. Calandra T, Glauser MP, Schellekens J, et al. Treatment of Gram negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double blind, randomized trial. J Infect Dis 1988;158:312-19.
79. Just HM, Voge W, Metzger M, et al. Treatment of intensive care unit patients with severe nosocomial infection. In: Morell A, Nydegger UE, eds. Clinical use of intravenous immunoglobulins. New York, Academic Press, 1986:346-52.
80. Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1991;325:73-80.
81. DeSimone C, Delogu G, Corbetta G. Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Crit Care Med 1988; 16:23-6.
82. Glinz W, Grob PVJ, Nydegger UE, et al. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. Intensive Care Med 1985; 11:288-94.
83. Gooding AM, Bastian JP, Peterson BM, et al. Safety and efficacy of intravenous immunoglobulin prophylaxis in pediatric head trauma patients: a double-blind controlled trial. J Crit Care 1993;4:212-16.
84. Ballow M, Cates KL, Rowe JC, et al. Development of the immune system in very low birth weight (less than 1500 g.) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res 1986;20:899-904.
85. Ruderman JW, Peter JB, Gall RC, et al. Prevention of hypogammaglobulinemia of prematurity with intravenous immune globulin. J Perinatol 1988;10:150-5.
86. Wilson CB, Lewis DB, Penix LA. The physiologic immunodeficiency of immaturity. In: Stiehm ER, ed. Immunologic disorders in infants and children. 4th ed. Philadelphia: Saunders, 1996:253-95.
87. Bussel JB. Intravenous gammaglobulin in the prophylaxis of late sepsis in very low birth weight infants: preliminary results of a randomized, double-blind, placebo-controlled trial. Rev Infect Dis 1990;12:S457-62.
88. Chirico G, Rondini G, Plebani A, et al. Intravenous gammaglobulin therapy for prophylaxis of infection in high risk neonates. J Pediatr 1987;110:437-42.
89. Clapp DW, Kliehman RM, Baley JE, et al. Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: report of a pilot study. J. Pediatr 1989;115:973-8.
90. Haque KN, Zaidi MH, Haque SK, et al. Intravenous immunoglobulin for prevention of sepsis in preterm and low birthweight infants. Pediatr Infect Dis 1986;5:622-5.
91. Kinney J, Mundorf L, Gleason C, et al. Efficacy and pharmacokinetics of intravenous immune globulin administration to high-risk neonates. Am J Dis Child 1991;145:1233-8.
92. Stabile A, Sopo SM, Romanelli V, et al. Intravenous immunoglobulin for prophylaxis of neonatal sepsis in premature infants. Arch Dis Child 1988;63:441-3.
93. Magny JF, Bremard Oury C, Brault D, et al. Intravenous immunoglobulin therapy for prevention of infection in high risk premature infants: report of multicenter, double blind study. Pediatrics 1991;88:437-43.
94. Baker CJ, Melish ME, Hall RT, et al. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. N Engl J Med 1992;327:213-9.
95. Weisman LE, Stoll BJ, Kueser TJ, et al. Intravenous immune globulin prophylaxis of late-onset sepsis in premature neonates. J Pediatr 1994;125:922-30.
96. Fanaroff AA, Korones SB, Wright LL, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. N Engl J Med 1994; 330:1107-13.
97. NIH Consensus Development Conference. Diseases, doses, recommendations for intravenous immunoglobulin. HLB Newslett Natl Inst Heart Lung Blood Dis 1990;6:73-8.
98. Jenson HB, Pollock BH. Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis. Pediatrics 99:e2, 1997.
99. Hill HR. Intravenous immunoglobulin use in the neonate: role in prophylaxis and therapy of infection. Pediatr Infect Dis J 1993;12:549-59.
100. Tutscha PJ. Diminishing morbidity and mortality of bone marrow transplantation. Vox Sang 1986;51(Suppl 2):87-94.
101. Graham-Pole J, Camitta B, Casper J, et al. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Bone Marrow Transplant 1988;3:559-66.
102. Sullivan KM. Immunoglobulin therapy in bone marrow transplantation. Am J Med 1987;83(Suppl 4A):34-5.
103. Sullivan KM. Intravenous immune globulin prophylaxis in recipients of a marrow transplant. J Allergy Clin Immunol 1989;84:632-9.
104. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323:705-12.
105. Keller T, McGrath K, Newland A, et al. Indications for use of intravenous immunoglobulin: recommendations of the Australasian Society of Blood Transfusion consensus symposium. Med J Aust 1993;159:204-6.
106. Rowe JM, Ciobanu N, Ascensao J, et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. Ann Intern Med 1994;120: 143-58.
107. Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant 1994;13:499-510.
108. Wolff SN, Fay JW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy: a study of the American Bone Marrow Transplant Group. Ann Intern Med 1993; 118:937-42.
109. Munster AM. Immunologic response of trauma and burns. Am J Med 1984;7:142-5.
110. Jones RJ, Roe EA, Gupta JL. Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients. Lancet 1980;2:1263-5.
111. Kefalides NA, Arana JA, Gazan A, et al. Role of infection in mortality from severe burns: evaluation of plasma, gamma globulin, albumin, and saline solution therapy in a group of Peruvian children. N Engl J Med 1962;267:317-23.
112. Shirani KZ, Vaughan GM, McManus AT, et al. Replacement therapy with modified immunoglobulin G in burn patients: preliminary kinetic studies. Am J Med 1984;76:175-80.
113. Pollack M. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J. Infect Dis 1983;147:1090-8.